KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Return on Equity (2018 - 2025)

Amneal Pharmaceuticals has reported Return on Equity over the past 8 years, most recently at 1.42% for Q4 2025.

  • Quarterly results put Return on Equity at 1.42% for Q4 2025, down 214.0% from a year ago — trailing twelve months through Dec 2025 was 1.42% (down 214.0% YoY), and the annual figure for FY2025 was 1.42%, down 308.0%.
  • Return on Equity for Q4 2025 was 1.42% at Amneal Pharmaceuticals, down from 0.52% in the prior quarter.
  • Over the last five years, Return on Equity for AMRX hit a ceiling of 5.52% in Q1 2024 and a floor of 1.62% in Q1 2023.
  • Median Return on Equity over the past 5 years was 0.05% (2021), compared with a mean of 0.11%.
  • Biggest five-year swings in Return on Equity: surged 714bps in 2024 and later plummeted -579bps in 2025.
  • Amneal Pharmaceuticals' Return on Equity stood at 0.05% in 2021, then tumbled by -2600bps to 1.35% in 2022, then skyrocketed by 58bps to 0.56% in 2023, then soared by 230bps to 0.73% in 2024, then crashed by -294bps to 1.42% in 2025.
  • The last three reported values for Return on Equity were 1.42% (Q4 2025), 0.52% (Q3 2025), and 0.42% (Q2 2025) per Business Quant data.